Moritz Spangemacher is a physician and PhD candidate at the Central Institute of Mental Health in Mannheim. He works in the department of molecular neuroimaging, led by Prof. Gerhard Gründer. His focus lies in the treatment of treatment-resistant depression and the research on psychotropic drugs. He works as a therapist in the EPisoDE study, which is a Phase-II-study that investigates the safety and efficacy of psilocybin in treatment-resistant depression. He is also partly responsible for the fMRI part of the study that explores the underlying mechanisms of the psilocybin effect. Furthermore, he investigates potential blood biomarkers for treatment response in the course of ketamine treatment.